RxDoctor Payments Data

Vinod Kapoor, MD

Neurology · Bayonne, NJNPI 1053457986

Payments from drug & device makers

$20,888in general payments, 2019–2025

Across 580 payments — averaging $36.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$8K
  • AbbVie$2K
  • Medtronic$1K
  • SK Life Science, Inc.$762
  • Monteris Medical Corporation$659
  • Biogen$633
  • plus $8K from 44 others

What the payments were for

  • Speaking & faculty fees$740%
  • Food & beverage$20,66199%
  • Education$1531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,888 in reported general payments places this provider in the 75th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$191,397
Medicare patients
289
Services billed
1,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5013$62,201
Nurtec OdtRimegepant Sulfate24$36,935
AptiomEslicarbazepine Acetate18$22,754
QuliptaAtogepant17$17,856
BotoxOnabotulinumtoxina13$15,525
Memantine Hcl ErMemantine Hcl132$14,638
VimpatLacosamide11$13,857
Memantine Hcl829$8,409
Lacosamide31$6,408
Levetiracetam286$4,419
Diclofenac Sodium ErDiclofenac Sodium187$3,888
CarbatrolCarbamazepine12$3,762
Carbamazepine114$3,257
Donepezil Hcl498$3,221
Gabapentin547$3,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$477$99,13637 claims
AbbVieQulipta, Botox$2,269$33,38130 claims
UCB, Inc.Vimpat$432$13,85711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 521 neurology providers in New Jersey.

Other neurology in Bayonne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →